

**Private and confidential**

9 December 2024

The Board of Directors  
Charmacy Pharmaceutical Co., Ltd.  
No. 235, Song Shan North Road  
Longhu District  
Shantou City  
Guangdong Province  
PRC

Dear Sirs,

**Re: Charmacy Pharmaceutical Co., Ltd. (the “Company”)  
Renewal of continuing connected transactions in relation to framework sales agreement and  
framework purchase agreement (the “Subject Matter”)**

We refer to the circular of the Company dated 9 December 2024 (the “Circular”) in relation to, among other things, the Subject Matter. Unless otherwise specified, capitalised terms used in this letter shall have the same meaning as ascribed to them in the Circular.

We hereby give, and we confirm that we have not withdrawn, our written consent to the issue of the Circular with the inclusion of our letter of advice dated 9 December 2024 and/or references to our name in the form and context in which they respectively appear.

We hereby consent to this letter being made available for inspection as described in the appendix to the Circular.

Yours faithfully,  
For and on behalf of  
Kingsway Capital Limited



---

Stanley Chung  
*Managing Director*